Swiss firm NovImmune secures highest private investment in 2009 so far
This article was originally published in Scrip
Executive Summary
NovImmune, a privately-held Swiss biotech company focused on immunology, has raised CHF62.5 million ($54.8 million) in a series B fundraising round led by BZ Bank Aktiengesellschaft.